Inhibitors of chronically active ras: potential for treatment of human malignancies

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Ras proteins are key signaling molecules and frequently mutated oncogenes in human cancers.
• Dysregulated Ras signaling drives cancer cell growth, making Ras a critical therapeutic target.
• Interfering with oncogenic Ras function selectively remains a significant challenge in cancer therapy.

Purpose of the Study:

• To review assays and compounds targeting enzymes involved in Ras post-translational modifications.
• To discuss inhibitors that disrupt Ras membrane binding and oncogenic signaling.
• To highlight recent patents and novel approaches for Ras inhibition.

Main Methods:

• Focus on enzymes responsible for Ras post-translational modifications: farnesyltransferase (FTase), geranylgeranyltransferase I (GGTase I), Rce1, isopentenylcysteine methyltransferase (Icmt), palmitoylating enzymes (PATs), and protein kinase C (PKC).
• Review of inhibitors targeting prenyl and post-prenyl processing steps of Ras.
• Examination of compounds competing with oncogenic Ras for membrane binding sites, such as farnesyl-S-thiosalicylic acid (FTS).

Main Results:

• Discusses the history, current status, and future prospects of various Ras inhibitor classes.
• Emphasizes recent patent literature concerning geranylgeranyltransferase inhibitors (GGTIs), Icmt inhibitors, and PAT inhibitors.
• Highlights novel strategies aimed at disrupting oncogenic Ras signaling pathways.

Conclusions:

• Inhibitors targeting Ras post-translational modifications and membrane localization represent a promising strategy for anticancer drug development.
• Further research into these inhibitors and novel approaches is essential for effective oncogenic Ras targeting.
• Recent advancements in patenting GGTIs, Icmt, and PAT inhibitors indicate active development in this field.